Artículos del autor

solaci

Day 2

STABILITY Trial: Daraplabid no benefits in chronic coronary artery disease

Daraplabid is a selective oral inhibitor of lipoprotein-associated phospholipase (Lp -PLA2)which is a potential agent for reducing...
solaci -
Day 1

CoreValve superior to surgical aortic valve replacement in high-risk patients

The aim of this study was to compare percutaneous aortic valve replacement (TAVR) with the self-expanding Valve...
solaci -
Day 1

SYMPLICITY HTN -3: Negative results of renal denervation in patients with resistant hypertension.

Previous studies have shown that renal denervation in a 3-year period, reduced the blood pressure in resistant...
solaci -
Day 3

CORAL: Angioplasty versus medical treatment of renal artery stenosis

Atherosclerotic stenosis of the renal artery is common in the elderly population. Previous clinical trials showed no...
solaci -
Day 3

ERASE: Endovascular treatment plus exercise versus exercise alone to treat claudication

Initial therapy for intermittent claudication has been historically the gear train, however, especially in recent years; the...
solaci -
Day 3

RADAR AF: High-frequency ablation versus pulmonary vein isolation to treat atrial fibrillation

Atrial fibrillation is initiated by focal triggers and maintained by an atrial substrate called fractioned complex of...
solaci -
Day 3

EU-PACT: Warfarin dose guided by genotype

Anticoagulation level in response to a fixed dose of warfarin is difficult to predict at the start...
solaci -
Day 3

ENGAGE AF-TIMI 48: Endoxaban versus warfarin in atrial fibrillation

The endoxaban is an oral direct inhibitor of factor Xa with a rapid onset of action and...
solaci -